Current controversies and future perspectives in chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 184, Issue 5, 2011, Pages 507-513

  Agustí, Alvar ^a,b   Vestbo, Jørgen ^c,d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Diagnosis; Epidemiology; Inflammation; Spirometry; Systems biology

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; ROFLUMILAST; TIOTROPIUM BROMIDE;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SOCIOECONOMICS;

DIAGNOSTIC TECHNIQUES, RESPIRATORY SYSTEM; DISEASE MANAGEMENT; HUMANS; MORBIDITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SURVIVAL RATE; WORLD HEALTH;

EID: 80052435472     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201103-0405PP     Document Type: Review

References (92)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Van Weel C, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555. (Pubitemid 47403272)
2. Fletcher C, Peto R, Tinker C, Speizer F. The natural history of chronic bronchitis and emphysema. New York: Oxford University Press; 1976.
3. Anto JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001;17:982-994. (Pubitemid 32600349)
4. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977;1:1645-1648. (Pubitemid 8124466)
5. Rennard SI, Vestbo J. Natural histories of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5:878-883.
6. Vestbo J, Prescott E, Lange P, Jensen G, Schnohr P, Appleyard M, Nyboe J, Gronbaek M. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Am J Respir Crit Care Med 1996;153:1530-1535. (Pubitemid 26141336)
7. Guerra S, Sherrill DL, Venker C, Ceccato CM, Halonen M, Martinez FD. Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Thorax 2009;64:894-900.
8. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the Lung Health Study. Am J Respir Crit Care Med 2001;164:358-364. (Pubitemid 32778199)
9. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-852. (Pubitemid 35178607)
10. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: Results from the TORCH Study. Am J Respir Crit Care Med 2008;178:332-338.
11. Kohansal R, Martinez-Camblor P, Agusti A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham Offspring Cohort. Am J Respir Crit Care Med 2009;180:3-10.
12. Gold DR, Wang X, Wypij D, Speizer FE, Ware JH, Dockery DW. Effects of cigarette smoking on lung function in adolescent boys and girls. N Engl J Med 1996;335:931-937. (Pubitemid 26314446)
13. Robbins DR, Enright PL, Sherrill DL. Lung function development in young adults: is there a plateau phase? Eur Respir J 1995;8:768-772.
14. Kerstjens HA, Rijcken B, Schouten JP, Postma DS. Decline of FEV1 by age and smoking status: facts, figures, and fallacies. Thorax 1997;52:820-827. (Pubitemid 27412566)
15. Barker DJ, Godfrey KM, Fall C, Osmond C, Winter PD, Shaheen SO. Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. BMJ 1991;303:671-675.
16. Shaheen SO, Barker JP, Holgate ST. Do lower respiratory tract infections in early childhood cause chronic obstructive pulmonary disease? Am J Respir Crit Care Med 1995;151:1649-1652.
17. Svanes C, Sunyer J, Plana E, Dharmage S, Heinrich J, Jarvis D, de Marco R, Norbäck D, Raherison C, Villani S, et al. Early life origins of chronic obstructive pulmonary disease. Thorax 2010;65:14-20.
18. de Marco R, Accordini S, Marcon A, Cerveri I, Antó JM, Gislason T, Heinrich J, Janson C, Jarvis D, Kuenzli N, et al.; European Community Respiratory Health Survey (ECRHS). Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am J Respir Crit Care Med. 2010;183:891-897.
19. Upton MN, Watt GC, Davey SG, McConnachie A, Hart CL. Permanent effects of maternal smoking on offsprings' lung function. Lancet 1998; 352:453. (Pubitemid 28362797)
20. Prescott E, Lange P, Vestbo J. Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. Eur Respir J 1999;13:1109-1114. (Pubitemid 29288937)
21. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, MacNee W, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010;182:598-604.
22. Loscalzo J, Kohane I, Barabasi AL. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol Syst Biol 2007;3:124.
23. Pillai SG, Kong X, Edwards LD, Cho MH, Anderson WH, Coxson HO, Lomas DA, Silverman EK; ECLIPSE and ICGN Investigators. Loci identified by genome-wide association studies influence different disease-related phenotypes in COPD. Am J Respir Crit CareMed.2010; 182:1498-1505.
24. Hersh CP, Pillai SG, Zhu G, Lomas DA, Bakke P, Gulsvik A, DeMeo DL, Klanderman BJ, Lazarus R, Litonjua AA, et al. Multistudy fine mapping of chromosome 2q identifies XRCC5 as a chronic obstructive pulmonary disease susceptibility gene. Am J Respir Crit Care Med 2010;182:605-613.
25. DeMeo DL, Mariani TJ, Lange C, Srisuma S, Litonjua AA, Celedon JC, Lake SL, Reilly JJ, Chapman HA, Mecham BH, et al. The SERPINE2gene is associated with chronic obstructive pulmonary disease. Am J Hum Genet 2006;78:253-264. (Pubitemid 43157565)
26. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011;12:56-68.
27. Barabasi AL. Network medicine-from obesity to the "diseasome."N Engl J Med 2007;357:404-407.
28. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in nonsmokers. Lancet 2009;374:733-743.
29. EisnerMD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, Romieu I, Silverman EK, Balmes JR; Committee on Nonsmoking COPD, Environmental and Occupational Health Assembly. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182:693-718.
30. Stein CE, Kumaran K, Fall CH, Shaheen SO, Osmond C, Barker DJ. Relation of fetal growth to adult lung function in south India. Thorax 1997;52:895-899. (Pubitemid 27473933)
31. Shaheen SO, Barker DJ, Shiell AW, Crocker FJ, Wield GA, Holgate ST. The relationship between pneumonia in early childhood and impaired lung function in late adult life. Am J Respir Crit Care Med 1994;149: 616-619. (Pubitemid 24082215)
32. Zwissler B, Kemming G, Habler O, Kleen M, Merket M, Haller M, Biegel J, Welte M, Peter K. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996;154:1671-1677. (Pubitemid 26424933)
33. Vandivier RW, Henson PM, Douglas IS. Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest 2006;129:1673-1682. (Pubitemid 43895000)
34. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, MacNee W, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-1138.
35. Tashkin DP. Frequent exacerbations of chronic obstructive pulmonary disease-a distinct phenotype? N Engl J Med 2010;363:1183-1184.
36. Enright PL. Are GOLDen slumbers drug induced? Am J Respir Crit Care Med 2008;177:1291-1292.
37. Fabbri LM, Boschetto P, Mapp C. Time to wake up! Am J Respir Crit Care Med 2008;177:1291-1292. (Pubitemid 351860943)
38. Quanjer PH, Enright PL, Miller MR, Stocks J, Ruppel G, Swanney MP, Crapo RO, Pedersen OF, Falaschetti E, Schouten JP, et al. The need to change the method for defining mild airway obstruction. Eur Respir J 2011;37:720-722.
39. Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O. Risk of over-diagnosis of COPD in asymptomatic elderly neversmokers. Eur Respir J 2002;20:1117-1122. (Pubitemid 35331867)
40. Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, Pavord ID. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000;356:1480-1485.
41. Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, Berry M, Parker D, Monteiro W, Pavord ID, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005;60:193-198. (Pubitemid 40380276)
42. Agusti A, Sobradillo P, Celli B. Addressing the complexity of COPD: from phenotypes and biomarkers to scale-free networks, systems biology and P4 medicine. Am J Respir Crit Care Med 2011;183:1129-1137.
43. Agusti AG. COPD, a multicomponent disease: implications for management. Respir Med 2005;99:670-682. (Pubitemid 40631293)
44. Agusti A, Calverley P, Celli B, Coxson H, Edwards L, Lomas D, MacNee W, Miller B, Rennard S, Silverman E, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11:122-136.
45. Agusti A. Chronic obstructive pulmonary disease: beyond the forced expiratory manoeuvre. Respiration 2008;75:136-137. (Pubitemid 351363865)
46. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-1012. (Pubitemid 38269277)
47. Puhan MA, Garcia-Aymerich J, Frey M, Ter RG, Anto JM, Agusti AG, Gomez FP, Rodriguez-Roisin R, Moons KG, Kessels AG, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE Index and the ADO Index. Lancet 2009;374:704-711.
48. Jones RC, Donaldson GC, Chavannes NH, Kida K, Dickson-Spillmann M, Harding S, Wedzicha JA, Price D, Hyland ME. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med 2009;180:1189-1195.
49. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005; 294:716-724. (Pubitemid 41159291)
50. Vestbo J, Rennard S. Chronic obstructive pulmonary disease biomarker (s) for disease activity needed-urgently. Am J Respir Crit Care Med 2010;182:863-864.
51. Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting b-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev [serial on the Internet]. 2007 [accessed June 2011];4:CD003794. Available from: http://www.cochrane.org/ reviews/clibintro.htm
52. Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev [serial on the Internet]. 2005 [accessed June 2011];2:CD002876.
53. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-555. (Pubitemid 351650535)
54. Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008;63:592-598. (Pubitemid 351969251)
55. Welte T,MiravitllesM, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:741-750.
56. Postma DS, Calverley P. Inhaled corticosteroids in COPD: a case in favour. Eur Respir J 2009;34:10-12.
57. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009;34:13-16.
58. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004;363:731-733. (Pubitemid 38296564)
59. Yang IA, Fong KM, Sim EH, Black PN, Lasserson TJ. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;CD002991.
60. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456. (Pubitemid 36173708)
61. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789. (Pubitemid 46294610)
62. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703.
63. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-694.
64. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH Study. Respir Res 2009;10:59.
65. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009;374:1171-1178.
66. Agusti A, Soriano JB. Dynamic hyperinflation and pulmonary inflammation: a potentially relevant relationship? European Respiratory Review 2006;15:68-71. (Pubitemid 47035704)
67. Mineo D, Ambrogi V, Cufari ME, Gambardella S, Pignotti L, Pompeo E, Mineo TC. Variations of inflammatory mediators and a1-antitrypsin levels after lung volume reduction surgery for emphysema. Am J Respir Crit Care Med 2010;181:806-814.
68. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Zaagsma J, Mueller A, Cornelissen PJ. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir Med 2010;104: 995-1004.
69. van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJ. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006;129:509-517.
70. Seemungal TAR, Wedzicha JA. Integrated care: a new model for COPD management? Eur Respir J 2006;28:4-6. (Pubitemid 44914252)
71. Casas A, Troosters T, Garcia-Aymerich J, Roca J, Hernandez C, Alonso A, del Pozo F, de Toledo P, Anto JM, Rodriguez-Roisin R, et al. Integrated care prevents hospitalisations for exacerbations in COPD patients. Eur Respir J 2006;28:123-130. (Pubitemid 44914269)
72. Garcia-Aymerich J, Hernandez C, Alonso A, Casas A, Rodriguez-Roisin R, Anto JM, Roca J. Effects of an integrated care intervention on risk factors of COPD readmission. Respir Med 2007;101:1462-1469. (Pubitemid 46844679)
73. Koff PB, Jones RH, Cashman JM, Voelkel NF, Vandivier RW. Proactive integrated care improves quality of life in patients with COPD. Eur Respir J 2009;33:1031-1038.
74. Galas DJ, Hood L. Systems biology and emerging technologies will catalyze the transition from reactive medicine to predictive, personalized, preventive and participatory (P4) medicine. IBC 2009;1:1-4.
75. Ganrot PO, Laurell CB, Eriksson S. Obstructive lung disease and trypsin inhibitors in a1-antitrypsin deficiency. Scand J Clin Lab Invest 1967; 19:205-208.
76. Turino G. M., Senior RM, B. D. Garg, S. Keller, M. M. Levi, I. Mandl. Serum elastase inhibitor deficiency and a1-antitrypsin deficiency in patients with obstructive emphysema. Science 1969;165:709-711.
77. Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med 1999;160:S49-S52.
78. Rahman I, MacNee W. Oxidant/antioxidant imbalance in smokers and chronic obstructive pulmonary disease. Thorax 1996;51:348-350. (Pubitemid 26140195)
79. Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, Agusti A, MacNee W. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005;60:293-300. (Pubitemid 40522365)
80. Burnett D, Chamba A, Hill SL, Stockley RA. Neutrophils from subjects with chronic obstructive lung disease show enhanced chemotaxis and extracellular proteolysis. Lancet 1987;2:1043-1046. (Pubitemid 17154783)
81. Noguera A, Batle S, Miralles C, Iglesias J, Busquets X, MacNee W, Agusti AG. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax 2001;56:432-437. (Pubitemid 32521359)
82. Pons AR, Noguera A, Blanquer D, Sauleda J, Pons J, Agusti AGN. Phenotypic characterisation of alveolar macrophages and peripheral blood monocytes in COPD. Eur Respir J 2005;25:647-652. (Pubitemid 40528757)
83. Majo J, Ghezzo H, Cosio MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J 2001;17:946-953. (Pubitemid 32600344)
84. Cosio M, Saetta M, Agusti A. Immunological aspects of COPD. N Engl J Med 2009;360:2445-2454.
85. Kasahara Y, Tuder RM, Cool CD, Voelkel NF. Expression of 15-lipoxygenase and evidence for apoptosis in the lungs from patients with COPD. Chest 2000;117:260S. (Pubitemid 30326979)
86. Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med 2001;163: 737-744. (Pubitemid 32230838)
87. Tuder RM, Petrache I, Elias JA, Voelkel NF, Henson PM. Apoptosis and emphysema: the missing link. Am J Respir Cell Mol Biol 2003;28: 551-554. (Pubitemid 36543401)
88. Morla M, Busquets X, Pons J, Sauleda J, MacNee W, Agusti AG. Telomere shortening in smokers with and without COPD. Eur Respir J 2006;27:525-528. (Pubitemid 43372526)
89. Tsuji T, Aoshiba K, Nagai A. Cigarette smoke induces senescence in alveolar epithelial cells. Am J Respir Cell Mol Biol 2004;31: 643-649. (Pubitemid 39587494)
90. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009; 135:173-180.
91. Rennard S. Inflammation and repair processes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:12S-16S.
92. Rennard SI, Togo S, Holz O. Cigarette smoke inhibits alveolar repair: a mechanism for the development of emphysema. Proc Am Thorac Soc 2006;3:703-708. (Pubitemid 44788228)